Abstract
Background There is limited information on the delivery of acute stroke therapies and secondary preventive measures and clinical outcomes over time in young adults with acute ischemic stroke (AIS). This study investigated whether advances in these treatments improved outcomes in this population.
Methods Using a prospective multicenter stroke registry in Korea, young adults (aged 18–50 years) with AIS hospitalized between 2008 and 2019 were identified. The observation period was divided into four epochs: 2008–2010, 2011–2013, 2014–2016, and 2017–2019. Secular trends for patient characteristics, treatments, and outcomes were analyzed.
Results A total of 7,050 eligible patients (mean age 43.1; men 71.9%) were registered. The mean age decreased from 43.6 to 42.9 years (Ptrend=0.01). Current smoking decreased, whereas obesity increased. Other risk factors remained unchanged. Intravenous thrombolysis and mechanical thrombectomy rates increased over time from 2008–2010 to 2017–2019 (9.5% to 13.8% and 3.2% to 9.2%, respectively; Ptrend’s<0.01). Door-to-needle time improved (Ptrend<.001), but onset-to-door and door-to-puncture time remained constant. Secondary prevention including the administration of dual antiplatelets for noncardioembolic minor stroke (26.7% to 47.0%), direct oral anticoagulants for atrial fibrillation (0.0% to 56.2%), and statins for large artery atherosclerosis (76.1% to 95.3%) increased (Ptrend’s<0.01). Outcome data were available from 2011. One-year mortality (2.5% in 2011–2013 and 2.3% in 2017–2019) and 3-month modified Rankin scale scores 0–1 (68.3% to 69.1%) and 0–2 (87.6% to 86.2%) remained unchanged. The one-year stroke recurrence rate increased (4.1% to 5.5%, Ptrend=0.04), altough the differnce was not significant after adjusting for sex and age.
Conclusion Improvements in the delivery of acute stroke treatments did not necessarily lead to better outcomes in young adults with AIS over the past decade, indicating a need for further progress.
Competing Interest Statement
H-J Bae reports grants from Astrazeneca, Bayer Korea, Bristol Myers Squibb Korea, Dong-A ST, Jeil Pharmaceutical Co., Ltd., Samjin Pharm, Takeda Pharmaceuticals Korea Co., Ltd., and Yuhan Corporation, roles as a principal investigator or co-investigator of clinical trials sponsored by Bayer, Bristol Myers Squibb, GNT Pharma, Korean Drug Co., Ltd., Shinpoong Pharm. Co., Ltd., and person fees from Amgen Korea, Bayer, Daiichi Sankyo, JW Pharmaceutical, Hanmi Pharmaceutical Co., Ltd., Otsuka Korea, SK chemicals, and Viatris Korea, outside the submitted work.
Funding Statement
This study was supported in part by the Korea Centers for Disease Control and Prevention (no. 2020ER620200f).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRBs of all participating centers (including Seoul National University Bundang Hospital) waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We extend our deepest gratitude for your meticulous review and comprehensive evaluation of our manuscript. The valuable feedback has helped us to improve the manuscript. We now provide responses to the reviewers and the revised manuscript. We are hopeful that we have adequately addressed the reviewers questions and have made the appropriate revisions to the manuscript. We are eager to receive further feedback and appreciate the time and effort the reviewers have dedicated to review of our manuscript.
Data Availability
The data used in this study may be made available upon request to the corresponding author.
